Azole Antifungal Consumption in Community Pharmacy Sales in Mainland Portugal: Trend Analysis from 2014 to 2023

Overview

Journal Antibiotics (Basel)

Date 2025 Jan 25

PMID 39858319

Authors

Sofia Moura

Paulo Duarte

Ana Sofia Oliveira

Jose Martinez-de-Oliveira

Ana Palmeira-de-Oliveira

Joana Rolo

Affiliations

Soon will be listed here.

Abstract

: Excessive or inadequate use of antimicrobial drugs may lead to the emergence of resistant strains. For this reason, it is important to monitor consumption indicators to assess drugs' utilization over time. This study aimed to analyze the consumption of medically prescribed azole antifungal drugs in mainland Portugal from 2014 to 2023, focusing on those directed to genital infections: fluconazole, isoconazole, itraconazole, and sertaconazole. : For each drug, the evaluated parameters were the total number of packages, number of packages per 1000 inhabitants, defined daily dose (DDD) per 1000 inhabitants per day, and total costs. For this purpose, we used data from community pharmacies' sales, which are available through INFARMED (the Portuguese national authority on medicines and health products). : Several trends emerged from data analysis. The COVID-19 pandemic negatively affected the consumption of all azole antifungal drugs included in this study. However, after 2020, fluconazole and sertaconazole consumption has been increasing. In the specific case of fluconazole, there was an increase in expenditure, although the total number of packages suffered a decrease over the 10-year study period. Additionally, the defined daily dose (DDD) per 1000 inhabitants per day for fluconazole and itraconazole was lower compared to estimates from the last available survey (2009). : Although our findings represent a lesser pressure on fungi, further monitoring is needed to better understand the evolution of fluconazole and itraconazole consumption over time, particularly due to the trends observed in this study.

References

Adriaenssens N, Coenen S, Versporten A, Goossens H . Outpatient systemic antimycotic and antifungal use in Europe: new outcome measure provides new insight. Int J Antimicrob Agents. 2013; 42(5):466-70. DOI: 10.1016/j.ijantimicag.2013.07.004. View

Shafiei M, Peyton L, Hashemzadeh M, Foroumadi A . History of the development of antifungal azoles: A review on structures, SAR, and mechanism of action. Bioorg Chem. 2020; 104:104240. DOI: 10.1016/j.bioorg.2020.104240. View

Amorim A, Guedes-Vaz L, Araujo R . Susceptibility to five antifungals of Aspergillus fumigatus strains isolated from chronically colonised cystic fibrosis patients receiving azole therapy. Int J Antimicrob Agents. 2010; 35(4):396-9. DOI: 10.1016/j.ijantimicag.2009.12.007. View

Cavaleiro I, Proenca L, Felix S, Salema-Oom M . Prevalence of yeast other than Candida albicans in denture wearers. J Prosthodont. 2013; 22(5):351-7. DOI: 10.1111/jopr.12005. View

Manuel da S Azevedo M, Cruz L, Pina-Vaz C, Goncalves-Rodrigues A . An overview about the medical use of antifungals in Portugal in the last years. J Public Health Policy. 2016; 37(2):200-15. DOI: 10.1057/jphp.2016.4. View

Silva A, Miranda I, Lisboa C, Pina-Vaz C, Rodrigues A . Prevalence, distribution, and antifungal susceptibility profiles of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis in a tertiary care hospital. J Clin Microbiol. 2009; 47(8):2392-7. PMC: 2725652. DOI: 10.1128/JCM.02379-08. View

Simoes-Silva L, Silva S, Santos-Araujo C, Sousa J, Pestana M, Araujo R . Oral Yeast Colonization and Fungal Infections in Peritoneal Dialysis Patients: A Pilot Study. Can J Infect Dis Med Microbiol. 2018; 2017:4846363. PMC: 5753011. DOI: 10.1155/2017/4846363. View

Fisher M, Alastruey-Izquierdo A, Berman J, Bicanic T, Bignell E, Bowyer P . Tackling the emerging threat of antifungal resistance to human health. Nat Rev Microbiol. 2022; 20(9):557-571. PMC: 8962932. DOI: 10.1038/s41579-022-00720-1. View

Faria-Ramos I, Neves-Maia J, Ricardo E, Santos-Antunes J, Silva A, Costa-de-Oliveira S . Species distribution and in vitro antifungal susceptibility profiles of yeast isolates from invasive infections during a Portuguese multicenter survey. Eur J Clin Microbiol Infect Dis. 2014; 33(12):2241-7. DOI: 10.1007/s10096-014-2194-8. View

10.

Fernandes M, Caetano C, Gaspar C, Oliveira A, Palmeira-de-Oliveira R, Martinez-de-Oliveira J . Uncovering the Yeast Diversity in the Female Genital Tract: An Exploration of Spatial Distribution and Antifungal Resistance. Pathogens. 2023; 12(4). PMC: 10145200. DOI: 10.3390/pathogens12040595. View

11.

Denning D . Antifungal drug resistance: an update. Eur J Hosp Pharm. 2022; 29(2):109-112. PMC: 8899664. DOI: 10.1136/ejhpharm-2020-002604. View

12.

Pinto E, Ribeiro I, Ferreira N, Fortes C, Fonseca P, Figueiral M . Correlation between enzyme production, germ tube formation and susceptibility to fluconazole in Candida species isolated from patients with denture-related stomatitis and control individuals. J Oral Pathol Med. 2008; 37(10):587-92. DOI: 10.1111/j.1600-0714.2008.00687.x. View

13.

Fernandes A, Azevedo N, Valente A, Dias M, Gomes A, Nogueira-Silva C . Vulvovaginal candidiasis and asymptomatic vaginal colonization in Portugal: Epidemiology, risk factors and antifungal pattern. Med Mycol. 2022; 60(5). DOI: 10.1093/mmy/myac029. View

14.

Rolo J, Faria-Goncalves P, Barata T, Oliveira A, Gaspar C, Ferreira S . Species Distribution and Antifungal Susceptibility Profiles of Isolates from Women with Nonrecurrent and Recurrent Vulvovaginal Candidiasis. Microb Drug Resist. 2021; 27(8):1087-1095. DOI: 10.1089/mdr.2020.0139. View

15.

Pathadka S, Yan V, Neoh C, Al-Badriyeh D, Kong D, Slavin M . Global Consumption Trend of Antifungal Agents in Humans From 2008 to 2018: Data From 65 Middle- and High-Income Countries. Drugs. 2022; 82(11):1193-1205. PMC: 9402496. DOI: 10.1007/s40265-022-01751-x. View

16.

Monteiro C, Pinheiro D, Maia M, Faria M, Lameiras C, Pinto E . Aspergillus species collected from environmental air samples in Portugal-molecular identification, antifungal susceptibility and sequencing of cyp51A gene on A. fumigatus sensu stricto itraconazole resistant. J Appl Microbiol. 2019; 126(4):1140-1148. DOI: 10.1111/jam.14217. View

17.

Sabino R, Goncalves P, Melo A, Simoes D, Oliveira M, Francisco M . Trends on Epidemiology-Perspectives from a National Reference Laboratory Surveillance Program. J Fungi (Basel). 2021; 7(1). PMC: 7825284. DOI: 10.3390/jof7010028. View

18.

Alhumaid S, Mutair A, Al Alawi Z, Alshawi A, Alomran S, Almuhanna M . Coinfections with Bacteria, Fungi, and Respiratory Viruses in Patients with SARS-CoV-2: A Systematic Review and Meta-Analysis. Pathogens. 2021; 10(7). PMC: 8308492. DOI: 10.3390/pathogens10070809. View

19.

Sabino R, Verissimo C, Brandao J, Alves C, Parada H, Rosado L . Epidemiology of candidemia in oncology patients: a 6-year survey in a Portuguese central hospital. Med Mycol. 2009; 48(2):346-54. DOI: 10.1080/13693780903161216. View

20.

Figueiral M, Fonseca P, Lopes M, Pinto E, Pereira-Leite T, Sampaio-Maia B . Effect of Denture-Related Stomatitis Fluconazole Treatment on Oral Candida albicans Susceptibility Profile and Genotypic Variability. Open Dent J. 2015; 9:46-51. PMC: 4319190. DOI: 10.2174/1874210601509010046. View